Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCN4 | Q9Y3Q4 | 2/20 | 0.69 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.69 |
| ▸ | HTR1A | P08908 | 1/20 | 0.69 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.69 |
| ▸ | DRD3 | P35462 | 1/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | KCNN2 | Q9H2S1 | 4/20 | 0.39 |
| ▸ | KCNN3 | Q9UGI6 | 4/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | KCNN1 | Q92952 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PGK1 | P00558 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29316696 | 1.00 | HCN4 (0.69) | HCN4CHRM2HTR1ASLC6A4DRD3 | |
| SCHEMBL9427546 | 1.00 | HCN4 (0.69) | HCN4CHRM2HTR1ASLC6A4DRD3 | |
| Hydrochloric Acid SCHEMBL384928 | 0.99 | HCN4 (0.68) | HCN4CHRM2HTR1ASLC6A4DRD3 | |
| SCHEMBL8372895 | 0.94 | HCN4 (0.61) | HCN4CHRM2HTR1ASLC6A4DRD3 | |
| SCHEMBL8370922 | 0.94 | HCN4 (0.61) | HCN4CHRM2HTR1ASLC6A4DRD3 | |
| SCHEMBL15858396 | 0.93 | HCN4 (0.61) | HCN4CHRM2HTR1ASLC6A4DRD3 | |
| SCHEMBL14813392 | 0.91 | HCN4 (0.68) | HCN4CHRM2HTR1ASLC6A4DRD3 | |
| SCHEMBL14696921 | 0.91 | HCN4 (0.68) | HCN4CHRM2HTR1ASLC6A4DRD3 | |
| SCHEMBL9427688 | 0.91 | HCN4 (0.68) | HCN4CHRM2HTR1ASLC6A4DRD3 | |
| SCHEMBL13155011 | 0.90 | HCN4 (0.58) | HCN4CHRM2HTR1ASLC6A4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101747-B2 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2012-01-24 | — | — | US | disclosed |
| US-8101747-B2 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2012-01-24 | — | — | US | disclosed |
| EP-2241554-B1 | Process for the synthesis of ivabradine and its pharmaceutically acceptable acid addition salts | SERVIER LAB (FR) | 2011-09-07 | — | — | EP | disclosed |
| EP-2241554-A1 | Process for the synthesis of ivabradine and its pharmaceutically acceptable acid addition salts | Les Laboratoires Servier (FR) | 2010-10-20 | — | — | EP | disclosed |
| WO-2010112704-A1 | NOVEL METHOD FOR THE SYNTHESIS OF IVABRADINE AND THE ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | LES LABORATOIRES SERVIER (FR) | 2010-10-07 | — | — | WO | disclosed |
| US-20100249397-A1 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2010-09-30 | — | — | US | disclosed |
| US-20100249397-A1 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2010-09-30 | — | — | US | disclosed |
| WO-2009158005-A1 | BENZAZEPINONE COMPOUNDS | CONCERT PHARMACEUTICALS, INC. (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249397-A1 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | CYP4F2, CYP2F1, CYP2D6 | HCN4 37/4885CHRM2 2611/4885HTR1A 1678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.